Proposal to Add FDG-PET as an Outcome Measure for Clinical Trials in Patients With Prodromal Lewy Body Dementia

Neurology. 2023 Oct 10;101(15):666-667. doi: 10.1212/WNL.0000000000207498. Epub 2023 Jul 3.

Authors

David G Lichter¹, Linda A Hershey²

Affiliations

¹ From the Department of Neurology (D.G.L.), Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY; and University of Oklahoma Health Sciences Center (retired) (L.A.H.), Oklahoma City. dlichter@buffalo.edu.
² From the Department of Neurology (D.G.L.), Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY; and University of Oklahoma Health Sciences Center (retired) (L.A.H.), Oklahoma City.

PMID: 37400241
PMCID: PMC10585694 (available on 2024-10-10)
DOI: 10.1212/WNL.0000000000207498

No abstract available

MeSH terms

Alzheimer Disease*
Fluorodeoxyglucose F18
Humans
Lewy Body Disease* / diagnostic imaging
Outcome Assessment, Health Care
Positron-Emission Tomography
Prodromal Symptoms

Substances

Fluorodeoxyglucose F18